2019 Volume 64 Issue 4 Pages 193-199
It has been widely understood and even accepted by the pharma industry that the hit-to-candidate exploratory phase in drug discovery requires 5 years of time and 2,500 test compounds to deliver a clinical candidate. Exscientia is the world-leading AI drug discovery company who directly challenges this pharma industry’s preconceptions of acceptable productivity. In fact, we have already demonstrated that our comprehensive AI platform can complete the exploration phase in a year with fewer than 400 compound syntheses/assays. Centaur ChemistTM is the central platform of Exscientia, combining the strengths of AI compound design and human strategic thinking. An overview of the platform and results of successful studies in the CNS and immuno-oncology areas will be presented, in order to convey how to make the drug discovery process more efficient.
